|
BCORL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.22430004917607E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.37189999757948E-08 |
| Normal-vs-Stage2 |
1.134090E-02 |
| Normal-vs-Stage3 |
3.20159998512537E-09 |
| Normal-vs-Stage4 |
5.16640000003399E-07 |
| Stage1-vs-Stage2 |
7.934500E-02 |
| Stage1-vs-Stage3 |
2.553600E-01 |
| Stage1-vs-Stage4 |
1.992180E-01 |
| Stage2-vs-Stage3 |
2.680400E-02 |
| Stage2-vs-Stage4 |
2.622000E-02 |
| Stage3-vs-Stage4 |
6.588400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.74190004034836E-09 |
| Normal-vs-AfricanAmerican |
1.841900E-02 |
| Normal-vs-Asian |
3.90200000000007E-05 |
| Caucasian-vs-AfricanAmerican |
3.917600E-01 |
| Caucasian-vs-Asian |
7.179800E-01 |
| AfricanAmerican-vs-Asian |
5.481200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.60609999999961E-05 |
| Normal-vs-Female |
1.7779999694767E-10 |
| Male-vs-Female |
3.576000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.24389999978503E-07 |
| Normal-vs-Age(41-60Yrs) |
3.28199999954926E-07 |
| Normal-vs-Age(61-80Yrs) |
6.79729994512712E-09 |
| Normal-vs-Age(81-100Yrs) |
2.736500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.703400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.855400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.223800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.261000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.978400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.606400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.822840E-04 |
| Classical-VS-Follicular |
9.957000E-01 |
| Classical-VS-Other |
2.533600E-01 |
| Classical-VS-Normal |
1.02250000022508E-07 |
| Tall-VS-Follicular |
2.561600E-03 |
| Tall-VS-Other |
7.062800E-01 |
| Tall-VS-Normal |
1.87269977303117E-10 |
| Follicular-VS-Other |
3.238600E-01 |
| Follicular-VS-Normal |
5.92269999999395E-05 |
| Other-VS-Normal |
3.222500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.27690000041004E-07 |
| Normal-vs-N1 |
3.5035000012229E-08 |
| N0-vs-N1 |
5.309600E-02 |
|
|
